28 terminated, 24 completed, 4 active not recruiting, 4 recruiting. 27 Phase 2, 21 Phase 1, 14 Phase 3, 2 Phase 4.
Follow idelalisib: new trials by email Literature Review of idelalisib trials Research Report on idelalisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Pirtobrutinib, Idelalisib - Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic | Phase 4 | Recruiting | Eli Lilly and Company | 150 | 2026-03-09 | 2026-11-04 |
| A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) DZD8586, Bendamustine, Idelalisib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 250 | 2025-09-08 | 2026-06-03 |
| A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis CAL101, Placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | Calluna Pharma AS | 150 | 2025-06-20 | 2026-04-27 |
| A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia | Phase 3 | Recruiting | BeOne Medicines | 250 | 2025-04-10 | 2026-09-28 |
| A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies Liso-cel, Idelalisib, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell | Phase 3 | Withdrawn | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2024-01-16 | 2024-04-02 | |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
| Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma Loncastuximab Tesirine, Idelalisib - Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Terminated | ADC Therapeutics S.A. | 6 | 2021-11-04 | 2023-10-23 |
| Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Pirtobrutinib, Idelalisib, Bendamustine - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Loxo Oncology, Inc. | 238 | 2021-03-09 | 2026-04-24 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma Idelalisib, Obinutuzumab - Follicular Lymphoma | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 5 | 2019-10-18 | 2024-11-21 |
| Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents Idelalisib, Rituximab, Ifosfamide - Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma | Phase 1 | Withdrawn | Gilead Sciences | 2019-06-01 | 2018-12-11 | |
| Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study idelalisib and rituximab - Chronic Lymphocytic Leukemia | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 104 | 2019-02-06 | 2022-05-12 | |
| Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland Idelalisib, Rituximab - Chronic Lymphocytic Leukaemia | Completed | Gilead Sciences | 112 | 2018-09-12 | 2019-04-12 | |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies Idelalisib 100 MG, Placebo Oral Tablet - B Cells-Tumors, B Cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 16 | 2018-07-31 | 2024-03-12 |
| REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia Idelalisib - Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | PETHEMA Foundation | 6 | 2018-07-01 | 2021-09-05 |
| Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma Idelalisib - Follicular Non-Hodgkin's Lymphoma Refractory | Completed | Gilead Sciences | 257 | 2018-05-25 | 2021-11-19 | |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Zydelig - Non Hodgkin Lymphoma, Follicular Lymphoma | Phase 2 | Completed | University of Maryland, Baltimore | 17 | 2017-10-23 | 2025-06-27 |
| Pembrolizumab + Idelalisib for Lung Cancer Study Pembrolizumab, Idelalisib - Non Small Cell Lung Cancer, Metastasis | Phase 1 / Phase 2 | Terminated | Asha Nayak | 4 | 2017-09-26 | 2024-02-28 |
| Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma Idelalisib - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Nordic Lymphoma Group | 36 | 2017-07-07 | 2021-10-13 |
| Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia Obinutuzumab, Idelalisib - Waldenstrom Macroglobulinemia | Phase 2 | Completed | French Innovative Leukemia Organisation | 50 | 2017-03-07 | 2023-08-29 |
Showing 20 of 65. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (38) · Lymphoma, Follicular (14) · Lymphoma, Non-Hodgkin (9) · Waldenstrom Macroglobulinemia (8) · Lymphoma, B-Cell, Marginal Zone (7) · Lymphoma, Mantle-Cell (5) · Leukemia (4) · Leukemia, Myeloid, Acute (4) · Lymphoma (4) · Lymphoma, B-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Lymphoma, Large B-Cell, Diffuse (3) · Hodgkin Disease (2) · Leukemia, B-Cell (2) · Leukemia, Myelomonocytic, Chronic (2)
Gilead Sciences (32) · Dana-Farber Cancer Institute (3) · OHSU Knight Cancer Institute (3) · Alliance for Clinical Trials in Oncology (2) · ADC Therapeutics S.A. (1) · Acerta Pharma BV (1) · Aptevo Therapeutics (1) · Asha Nayak (1) · BeOne Medicines (1) · Calluna Pharma AS (1) · Dizal Pharmaceuticals (1) · Eli Lilly and Company (1) · Fondazione Italiana Linfomi - ETS (1) · Fred Hutchinson Cancer Center (1) · French Innovative Leukemia Organisation (1)
United States (48) · United Kingdom (23) · France (22) · Italy (22) · Spain (17) · Poland (16) · Germany (14) · Australia (12) · Belgium (11) · Canada (10) · Czechia (10) · Austria (8) · Hungary (8) · Ireland (7) · Israel (7)
Thomas Jahn, MD (2) · Anke Muth (1) · Antonio Cuneo (1) · Daniel Hommes (1) · Douglas Gladstone, MD (1) · Friedrich Horak, MD (1) · Gian Matteo Rigolin (1) · Jean Yared, MD (1) · Jennifer B Brown, MD, PhD (1)
PMID 21816833, PMID 24615776, PMID 24615777, PMID 24615778, PMID 26472751, PMID 28314699, PMID 29296805, PMID 31723767, PMID 32599655, PMID 33297794, PMID 24450857, PMID 24450858, PMID 26915677, PMID 26968534, PMID 27247136, PMID 28178345, PMID 28257752, PMID 28327905, PMID 28424162, PMID 30967392, PMID 30995176, PMID 31729982, PMID 32459600, PMID 32856068, PMID 33516721, PMID 33709202, PMID 33961019, PMID 34414843, PMID 38620092, PMID 39499299, PMID 39863139, PMID 40479620, PMID 41124966, PMID 42329537
2015 (5), U10CA031946 (2), 2014 (1), 2017 (1), P01CA018029 (1), P30CA015704 (1), P30CA069533 (1), P50CA097274 (1), R21CA159265 (1)